Our study challenges the notion that type I JAK2is such as ruxolitinib are relatively ineffective for the treatment of CRLF2/JAK2 mutant leukemia due to paradoxical JAK2Y1007/1008 hyperphosphorylation (Weigert et al. 2012; Wu et al. 2015). The gene discussed is JAK2; the disease is leukemia.